Ben Arush M Weyl, Ben Barak A, Maurice S, Livne E
Department of Pediatric Hematology, Meyer Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
Pediatr Hematol Oncol. 2007 Mar;24(2):111-5. doi: 10.1080/08880010601052381.
This pilot study aimed at determining serum VEGF levels (S-VEGF) at diagnosis and at restaging in children with Hodgkin lymphoma, and investigating whether this parameter provides prognostic information for remission after 2 courses of chemotherapy. PET-CT fusion was performed to assess response to treatment. Changes in S-VEGF levels were found to correlate with response to treatment for most of the children. This provides a rationale for exploring clinical interest in S-VEGF measurements in a larger group of children with Hodgkin lymphoma, and using the test for clinical trials of anti-angiogenic therapies.
这项初步研究旨在测定霍奇金淋巴瘤患儿诊断时及再分期时的血清血管内皮生长因子水平（S-VEGF），并研究该参数是否能为两疗程化疗后的缓解情况提供预后信息。采用PET-CT融合技术评估治疗反应。结果发现，大多数患儿的S-VEGF水平变化与治疗反应相关。这为在更大规模的霍奇金淋巴瘤患儿群体中探索S-VEGF检测的临床意义以及将该检测用于抗血管生成疗法的临床试验提供了理论依据。
